SPRO News and Press, Spero Therapeutics Inc.

CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced t...

CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced tha...

2024-05-15 16:10:58 ET More on Spero Therapeutics Spero Therapeutics Delivers On Game Plan To Create Shareholder Value Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript Spero Therapeutics Q1 2024 Earnings Preview Spero Therapeutics Q4 2023 Earn...

On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTI Received FDA Fast...

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced tha...

2024-04-23 11:37:17 ET Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from ...

2024-03-15 16:45:20 ET More on Spero Therapeutics Spero Therapeutics says cash and cash equivalents as of December 31 were about $76.3M Read the full article on Seeking Alpha For further details see: Spero Therapeutics files $300M mixed securities shelf

2024-03-14 09:22:00 ET DENVER, Colo., Mar 14, 2024 ( 247marketnews.com )- This morning’s notable listings with recent news include Lithium Americas Corp. (NYSE: LAC ), Robinhood Markets, Inc. (NASDAQ: HOOD ), Brera Holding ( NASDAQ:BREA ), Spero Therapeutics, Inc. ...

2024-03-14 09:06:04 ET DENVER, Colo., Mar 14, 2024 ( 247marketnews.com )- Spero Therapeutics, Inc. (NASDAQ: SPRO ) reported its fourth quarter and full year 2023 financial results, and provided a business update. “2023 was a productive year for Spero and we have been...

2024-03-13 17:45:09 ET Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Conference Call March 13, 2024, 04:30 PM ET Company Participants Michael Wood - Managing Director of LifeSci Advisors Sath Shukla - CEO Kamal Hamed - CMO Esther Rajavelu - CFO and Chief B...